ロード中...
CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1
CpG oligodeoxynucleotides, as a ligand of toll-like receptor (TLR)-9, have demonstrated promising antitumor effects in some clinical trials; however, its toxicity and low efficacy as a systemic therapy has limited its therapeutic applications. In order to improve its therapeutic efficacy, we investi...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342548/ https://ncbi.nlm.nih.gov/pubmed/27602959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11833 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|